US 11,878,980 B2
Solid forms of TTK inhibitor
Sze-Wan Li, Toronto (CA); Heinz W. Pauls, Oakville (CA); and Peter Brent Sampson, Oakville (CA)
Assigned to UNIVERSITY HEALTH NETWORK, Toronto (CA)
Filed by UNIVERSITY HEALTH NETWORK, Toronto (CA)
Filed on Aug. 27, 2021, as Appl. No. 17/459,725.
Application 17/459,725 is a continuation of application No. 16/806,392, filed on Mar. 2, 2020, granted, now 11,104,681.
Application 16/806,392 is a continuation of application No. 16/318,426, granted, now 10,584,130, issued on Mar. 10, 2020, previously published as PCT/CA2017/050848, filed on Jul. 13, 2017.
Claims priority of provisional application 62/363,424, filed on Jul. 18, 2016.
Prior Publication US 2022/0089601 A1, Mar. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 487/04 (2006.01); A61K 31/519 (2006.01); A61P 35/00 (2006.01); C30B 29/58 (2006.01); C30B 7/14 (2006.01); C30B 7/02 (2006.01)
CPC C07D 487/04 (2013.01) [A61K 31/519 (2013.01); A61P 35/00 (2018.01); C30B 7/02 (2013.01); C30B 7/14 (2013.01); C30B 29/58 (2013.01); C07B 2200/13 (2013.01)] 8 Claims
 
1. A hydrobromide salt of compound (I) represented by the following structure formula:

OG Complex Work Unit Chemistry
or a solvate thereof, wherein the molar ratio between compound (I) and hydrobromic acid is 1:1.